ATRA — Atara Biotherapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1604464 ·
Last close
$6.50
Market Cap
$66.22M
52W High
$19.15
52W Low
$3.92
ADV30
24,802
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 1,224,000 | 959,000 | -2,970,000 | -2,229,000 | 18,607,000 | 4,055,000 | 56,509,000 |
| Jun 2026 | 630,000 | 439,000 | -4,720,000 | -4,834,000 | 21,024,000 | 3,221,000 | 58,020,000 |
| Mar 2026 | 516,000 | 392,000 | -3,369,000 | -4,145,000 | 19,997,000 | 8,360,000 | 57,309,000 |
| Dec 2025 | 1,595,000 | 1,491,000 | -2,563,000 | -3,406,000 | 20,235,000 | 8,482,000 | 58,737,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-12,987,000
Investing CF
$2,647,000
Financing CF
$8,653,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.08
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,033,073,000
Inventory
$0
Receivables
$691,000
ST Investments
$5,862,000
EBIT TTM
$-12,698,000
Pretax Income TTM
$-14,613,000
Interest Exp TTM
$1,915,000
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$3,965,000
EBITDA
$838,000
Free Cash Flow
$-12,522,250
Enterprise Value
$77,012,600
Total Cash
$9,917,000
Total Debt
$8,482,000
Shares Out
10,188,438
Trailing EPS
$-1.12
Book Value
$-3.72
ROE
—
ROA
-0.0%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 120,772,000 | 35,862,000 | 32,688,000 | 20,235,000 | 58,737,000 | -38,502,000 | -50,940,000 |
| Dec 2024 | 128,940,000 | -83,438,000 | -85,403,000 | 109,098,000 | 206,381,000 | -97,283,000 | -68,717,000 |
| Dec 2023 | 8,573,000 | -276,006,000 | -276,126,000 | 165,504,000 | 264,735,000 | -99,231,000 | -192,977,000 |
| Dec 2022 | 63,573,000 | -280,513,000 | -228,302,000 | 376,420,000 | 249,780,000 | 126,640,000 | -270,430,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$-41,876,000
NetIncome TTM
$-16,688,000
OpCashFlow TTM
—
Assets (Latest)
$21,024,000
Forward EPS
$2.56
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CRDF | Cardiff Oncology, Inc. | $65.85M | $0.85 | — |
| AVXL | ANAVEX LIFE SCIENCES CORP. | $68.60M | $0.74 | — |
| CSBR | CHAMPIONS ONCOLOGY, INC. | $63.91M | $4.59 | — |
| VISK | Viskase Holdings, Inc. | $63.49M | $4.43 | — |
| NMRA | Neumora Therapeutics, Inc. | $62.85M | $0.33 | — |
News headlines (Yahoo Finance, 1h cache)
Atara Biotherapeutics: Q3 Earnings Snapshot
2026-11-10 21:53 · Yahoo
Atara Biotherapeutics Announces Third Quarter 2026 Financial Results and Operational Progress
2026-11-10 21:05 · Yahoo
Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration
2026-10-14 12:05 · Yahoo
Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration
2026-09-30 12:05 · Yahoo
Atara Biotherapeutics Announces Changes to Its Board of Directors
2026-06-12 20:00 · Yahoo
FDA Resubmission Path for Tab-cel Keeps Atara’s (ATRA) Regulatory Timeline Alive
2026-05-07 15:03 · Yahoo
Atara Biotherapeutics, Inc. (ATRA) Registers Possible Resale of 400K Common Shares Tied to HCR Warrant Exercise
2026-04-03 00:02 · Yahoo
Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress
2026-08-12 20:05 · Yahoo
Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx
2026-04-01 12:01 · Yahoo
Biotech Stocks Surge As UniQure 'Nail-Biting Journey' Comes To An End
2026-06-17 20:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.